Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Rembrandt Institute for Cardiovascular Sciences Background Venous bypass grafts may have limited patency due to excessive intimal hyperplasia and accelerated atherosclerosis. YAP-TAZ signaling regulates cellular responses to biomechanical cues, such as disturbed flow or vessel distention as seen in vein grafts. YAP activation leads to inflammation and angiogenesis, which both contribute to vein graft atherosclerosis. Inhibition of YAP-TAZ attenuates naive atherogenesis, but its potential to inhibit intraplaque angiogenesis and reduce vein graft atherosclerosis has not been explored. Methods Saphenous vein progenitor cells (SVPs) were subjected to mechanical strain in vitro to assess YAP activation. IHC to assess YAP-expression was performed on vein grafts from pigs as well as ex vivo cultured human saphenous veins. Furthermore, YAP-IHC was performed on murine vein grafts from hypercholesterolemic ApoE3*Leiden mice harvested at early, mid- and late-stage disease timepoints to assess optimal treatment window. In a separate experiment, mice (n=11-13/group) underwent bypass surgery and were treated with the FDA-approved YAP-TAZ inhibitor Verteporfin (50 mg/kg) or vehicle 3 times/week from day 10 until sacrifice (day 28). Ultrasound was used to longitudinally quantify vascular remodeling. Vein grafts were harvested and processed for morphometric and compositional analysis. Results Mechanical strain induced activation of YAP and its downstream targets (Ctgf, Cyr61) in SVPs, which was inhibited by Verteporfin (confirmed by WB, IP and qPCR). Moreover, YAP was abundantly expressed in pig vein graft lesions, whilst Verteporfin blocked YAP expression in ex vivo cultured human saphenous veins after exposure to disturbed flow. In addition, YAP was increasingly expressed during vein graft lesion development in mice, reaching its peak around day 14, which coincides with the initiation of intraplaque angiogenesis. Furthermore, YAP was predominantly expressed in luminal and adventitial endothelial cells. Analysis of ultrasound demonstrated that Verteporfin prevented vein graft thickening in mice over time. End-point histology revealed that the intima/media ratio was significantly decreased by Verteporfin treatment (37%, p=0.001). Intraplaque angiogenesis was also reduced (34%, p=0.002), whilst neovessel maturation was improved upon verteporfin treatment. The vessel wall ACTA2 content was reduced (42%, p=0.023), whilst collagen was not altered between both groups, indicating that Verteporfin diminished the fibroproliferative response without affecting vessel wall stability. Conclusion Verteporfin inhibited YAP-TAZ activation induced by mechanical strain in vitro (SVPs) as well as ex vivo (cultured human saphenous veins). In vivo, Verteporfin treatment resulted in a significant decrease of vein graft atherosclerosis and intraplaque angiogenesis. Therefore, therapeutic targeting of YAP-TAZ using Verteporfin might be a new candidate to improve vein graft patency.

Gene Transfer of A Broad Spectrum Cc-Chemokine Inhibitor Reduces Vein Graft Atherosclerosis in Apolipoprotein E-Knockout Mice

Accelerated Atherosclerosis and Calcification in Vein Grafts

Topical Hdl Administration Reduces Vein Graft Atherosclerosis in Apo E Deficient Mice

Gene Transfer of Calcitonin Gene-Related Peptide Inhibits Macrophages and Inflammatory Mediators in Vein Graft Disease

MicroRNA-221 sponge therapy attenuates neointimal hyperplasia and improves blood flows in vein grafts

Adenovirus-Mediated Gene Transfer Of Microrna-21 Sponge Inhibits Neointimal Hyperplasia In Rat Vein Grafts

Local Gene Transfer of Tissue Inhibitor of Metalloproteinase-2 Influences Vein Graft Remodeling in a Mouse Model

P38 MAPK Inhibitor, CBS3830 Limits Vascular Remodelling in Arterialised Vein Grafts.

PFKFB3 gene deletion in endothelial cells inhibits intraplaque angiogenesis and lesion formation in a murine model of venous bypass grafting

Vein graft disease in a knockout mouse model of hyperhomocysteinaemia

Mouse Model of Venous Bypass Graft Arteriosclerosis

Therapeutic inhibition of biomechanically-activated YAP-TAZ signaling prevents vein graft atherosclerosis

Atorvastatin Reduces Accumulation of Vascular Smooth Muscle Cells to Inhibit Intimal Hyperplasia Via P38 MAPK Pathway Inhibition in a Rat Model of Vein Graft.

MicroRNA-146a sponge therapy suppresses neointimal formation in rat vein grafts.

Exacerbated Vein Graft Arteriosclerosis in Protein Kinase Cδ–null Mice

Abstract 18700: Accelerated Endothelial Regeneration and Survival Attenuate Vein Graft Atherosclerosis via Terahydrobiopterin-Dependent eNOS Coupling

Empirical Study of Transfecting Early Growth Response Gene‐1 DNA Enzyme to Prevent Intimal Hyperlasia of Autogenous Vein Graft in Rats

Reduced Neointima Hyperplasia of Vein Bypass Grafts in Intercellular Adhesion Molecule-1–Deficient Mice

Adenovirus Mediated Endothelial Nitric Oxide Synthase Gene Transfer Prevents Restenosis of Vein Grafts

Early Growth Response Gene-1 Decoy Oligonucleotides Inhibit Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia of Autogenous Vein Graft in Rabbits.

Inhibition of Neointima Hyperplasia of Mouse Vein Grafts by Locally Applied Suramin